Literature DB >> 34142718

Acute morphine blocks spinal respiratory motor plasticity via long-latency mechanisms that require toll-like receptor 4 signalling.

Arash Tadjalli1,2, Yasin B Seven1,2, Abhisheak Sharma3, Christopher R McCurdy4, Donald C Bolser1,5, Erica S Levitt1,6, Gordon S Mitchell1,2.   

Abstract

KEY POINTS: While respiratory complications following opioid use are mainly mediated via activation of mu opioid receptors, long-latency off-target signalling via innate immune toll-like receptor 4 (TLR4) may impair other essential elements of breathing control such as respiratory motor plasticity. In adult rats, pre-treatment with a single dose of morphine blocked long-term facilitation (LTF) of phrenic motor output via a long-latency TLR4-dependent mechanism. In the phrenic motor nucleus, morphine triggered TLR4-dependent activation of microglial p38 MAPK - a key enzyme that orchestrates inflammatory signalling and is known to undermine phrenic LTF. Morphine-induced LTF loss may destabilize breathing, potentially contributing to respiratory side effects. Therefore, we suggest minimizing TLR-4 signalling may improve breathing stability during opioid therapy. ABSTRACT: Opioid-induced respiratory dysfunction is a significant public health burden. While respiratory effects are mediated via mu opioid receptors, long-latency off-target opioid signalling through innate immune toll-like receptor 4 (TLR4) may modulate essential elements of breathing control, particularly respiratory motor plasticity. Plasticity in respiratory motor circuits contributes to the preservation of breathing in the face of destabilizing influences. For example, respiratory long-term facilitation (LTF), a well-studied model of respiratory motor plasticity triggered by acute intermittent hypoxia, promotes breathing stability by increasing respiratory motor drive to breathing muscles. Some forms of respiratory LTF are exquisitely sensitive to inflammation and are abolished by even a mild inflammation triggered by TLR4 activation (e.g. via systemic lipopolysaccharides). Since opioids induce inflammation and TLR4 activation, we hypothesized that opioids would abolish LTF through a TLR4-dependent mechanism. In adult Sprague Dawley rats, pre-treatment with a single systemic injection of the prototypical opioid agonist morphine blocks LTF expression several hours later in the phrenic motor system - the motor pool driving diaphragm muscle contractions. Morphine blocked phrenic LTF via TLR4-dependent mechanisms because pre-treatment with (+)-naloxone - the opioid inactive stereoisomer and novel small molecule TLR4 inhibitor - prevented impairment of phrenic LTF in morphine-treated rats. Morphine triggered TLR4-dependent activation of microglial p38 MAPK within the phrenic motor system - a key enzyme that orchestrates inflammatory signalling and undermines phrenic LTF. Morphine-induced LTF loss may destabilize breathing, potentially contributing to respiratory side effects. We suggest minimizing TLR-4 signalling may improve breathing stability during opioid therapy by restoring endogenous mechanisms of plasticity within respiratory motor circuits.
© 2021 The Authors. The Journal of Physiology © 2021 The Physiological Society.

Entities:  

Keywords:  (+)-naloxone; breathing; inflammation; intermittent hypoxia; morphine; neuroplasticity; opioid; phrenic motor neuron; spinal cord; toll-like receptor 4

Mesh:

Substances:

Year:  2021        PMID: 34142718      PMCID: PMC8437142          DOI: 10.1113/JP281362

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   6.228


  123 in total

Review 1.  Glia: novel counter-regulators of opioid analgesia.

Authors:  Linda R Watkins; Mark R Hutchinson; Ian N Johnston; Steven F Maier
Journal:  Trends Neurosci       Date:  2005-10-24       Impact factor: 13.837

2.  Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo.

Authors:  Mohammad Hajiha; Marq-André DuBord; Hattie Liu; Richard L Horner
Journal:  J Physiol       Date:  2009-04-29       Impact factor: 5.182

Review 3.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

4.  Prevalence and predictors of persistent post-surgical opioid use: a prospective observational cohort study.

Authors:  N Stark; S Kerr; J Stevens
Journal:  Anaesth Intensive Care       Date:  2017-11       Impact factor: 1.669

5.  Multi-Level Regulation of Opioid-Induced Respiratory Depression.

Authors:  Barbara Palkovic; Vitaliy Marchenko; Edward J Zuperku; Eckehard A E Stuth; Astrid G Stucke
Journal:  Physiology (Bethesda)       Date:  2020-11-01

Review 6.  MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.

Authors:  Bozena Kaminska
Journal:  Biochim Biophys Acta       Date:  2005-09-08

Review 7.  Morphine-6-glucuronide: morphine's successor for postoperative pain relief?

Authors:  Eveline L A van Dorp; Raymonda Romberg; Elise Sarton; James G Bovill; Albert Dahan
Journal:  Anesth Analg       Date:  2006-06       Impact factor: 5.108

8.  Cervical spinal 5-HT2A and 5-HT2B receptors are both necessary for moderate acute intermittent hypoxia-induced phrenic long-term facilitation.

Authors:  Arash Tadjalli; Gordon S Mitchell
Journal:  J Appl Physiol (1985)       Date:  2019-06-20

9.  Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury.

Authors:  Amanda Ellis; Peter M Grace; Julie Wieseler; Jacob Favret; Kendra Springer; Bryce Skarda; Monica Ayala; Mark R Hutchinson; Scott Falci; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2016-08-09       Impact factor: 7.217

10.  Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use.

Authors:  Susan L Calcaterra; Traci E Yamashita; Sung-Joon Min; Angela Keniston; Joseph W Frank; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2016-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.